Live Telecast, "STEM CELL THERAPY & NEUROLOGICAL DISORDERS" on 21st April 2018 at 3.30 PM on Z-24TAAS_HITGUJ By Dr. Anant Bagul   :*: Upcomming Events: “2ND INTERNATIONAL REGENERATIVE MEDICINE CONCLAVE ON 13TH MAY 2018”  

Worldwide References

Autism References
Cerebral Palsy References
Diabetes Melitus References
Alzimers Disease References
Cerebellar Ataxia References
Chronic Renal Failure References
DMD Limb Girdle References
Hemiplegia References
Liver Cirrhosis References
MND References
Multiple Sclerosis References
  • Multiple Sclerosis reversed' with stem cell research11:57 30 January 2009 by Linda Geddes Three years later, 17 of the (24) patients had improved by at least one point on a standard disability scale, while none of the patients had deteriorated.
  • Bone Marrow Stem Cells Show Exciting Potential For Multiple Sclerosis research Medical News Today Article Date: 06 May 2010 - 1:00PDT The procedure was well tolerated and the participants were followed up for a year. No serious adverse effects were encountered. The results of clinical scores were consistent with stable disease. The results of neurophysiological tests raised the possibility of benefit. (see below study)
  • Multiple Sclerosis 'reversed' with stem cell research11:57 30 January 2009 by Linda Geddes Three years later, 17 of the (24) patients had improved by at least one point on a standard disability scale, while none of the patients had deteriorated.
    * .html
  • Safety and Feasibility of Autologous Bone Marrow Cellular research in Relapsing-Progressive Multiple Sclerosis The lack of serious adverse effects and the suggestion of a beneficial effect in this small sample of patients with progressive disease justify conducting a larger phase II/III study C M Rice1, E A Mallam1, A L Whone1,2,3, P Walsh1, D J Brooks2, N Kane1, S R Butler3, D I Marks4 and N J Scolding1� Clinical Pharmacology & Therapeutics (2010) 87 6, 679–685. doi:10.1038/clpt.2010.44
  • Early-Stage Multiple Sclerosis Reversed By Stem Cell Transplant Medical News Today Article Date: 31 Jan 2009 – Researchers from Northwestern University's Feinberg School of Medicine appear to have reversed the neurological dysfunction of early-stage multiple sclerosis patients by transplanting their own immune stem cells into their bodies and thereby"resetting" their immune systems.
  • Stem Cell Transplant Study Shows Promise For Multiple Sclerosis Article Date: 12 Jun 2009 - 3:00 PDT “Some 81 percent of patients in the early phase study showed signs of improvement with the research, which used chemoresearch to destroy the immune system, and injections of the patient's bone marrow cells taken beforehand to rebuild it.
  • Early-Stage Multiple Sclerosis Reversed By Stem Cell Transplant Medical News Today Article Date: 31 Jan 2009 - 0:00 PDT "This is the first time we have turned the tide on this disease," said principal investigator Richard Burt, M.D. chief of immunoresearch for autoimmune diseases at the Feinberg School
  • Fat Tissue Stem Cells Offer Hope For Multiple Sclerosis research Article Date: 24 Apr 2009 - 1:00 PDT "All three patients in our study showed dramatic improvement in their condition after the course of SVF research.
  • Immune System Helps Transplanted Stem Cells Navigate In Central Nervous System Medical News Today Article Date: 02 Jun 2010 - 5:00 PDT "In this study, we've taken an important step by showing the navigational cues in an inflammatory environment like MS that guide stem cells,"
Optic Nerve Atrophy References

Worldwide Publications

Stem Cell research For Blindness Shows Promise In Trials

The first published results of trials using cells derived from human embryonic stem cells appear to show they have passed an initial safety hurdle. In The Lancet this week, researchers report that two nearly blind patients, one with Stargardt's macular dystrophy and the other with dry age-relatedmacular degeneration (the leading cause of blindness in developed countries), showed measurable improvements in vision that lasted for more than four months after receiving injections of retinal pigment epithelium cells derived from human embryonic stem cells.

The retinal pigment epithelium (RPE) cells were developed by the US stem cell company Advanced Cell Technology (ACT), and the trials were conducted at the Jules Stein Eye Institute at the University of California, Los Angeles. The report appeared online inThe Lancet on Monday 23 January.

Both trials are designed as prospective "open label" trials to test the safety and tolerability of sub-retinal transplantation of RPE cells made from stem cells derived from human embryos. As well as these two trials taking place in the US, another trial for SMD is just starting in the UK, and the first patient was treated at Moorfields Eye Hospital in London last Friday. The researchers write in The Lancet.

"It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients."

The apparent success of the trials, which at best showed that vision improved slightly, and at worst, that it did not deteriorate and there were no adverse safety issues, could signify a major boost to the field of stem cell research which has found itself in the doldrums lately. And in this particular case, they offer hope to millions of people with AMD, whose numbers are increasing every year. In the US alone, the number of people with AMD is estimated to reach 2.95 million by 2020, according to the Centers for Disease Control and Prevention (CDC).

Macular degeneration, often called age-related macular degeneration (AMD), is an eye disorder associated with aging where people's vision becomes less sharp and they gradually lose central vision, which is essential every day tasks such as reading and driving. AMD affects the macula, the middle part the retina that allows the eye to see fine details. There are two forms of AMD, wet and dry. And although dry is by far the most common form of AMD, unfortunately drugs are only available for wet AMD. Dr Robert Lanza is the chief scientific officer of ACT and the senior author of the paper. He told the press the "safety and engraftment data to date look very encouraging", and that despite the progressive nature of Stargardt's macular dystrophy (SMD) and AMD.

Scientists perform Ontario's first cardiac stem cell transplant

Source: University of Toronto
Date: January 27, 2012


University of Toronto faculty members performed the first cardiac stem cell transplant in Ontario recently, using stem cells derived from the patient's own bone marrow, isolated completely within the operating room, and implanted into the heart at the time of coronary bypass surgery. The stem cells were injected following coronary artery bypass graft (CABG) surgery, by a multi-disciplinary team led by Dr. Terrence Yau, a U of T professor of surgery and director of the Cardiac Stem Cell research Program at the hospital’s Peter Munk Cardiac Centre, part of the University Health Network (UHN).

The Toronto Star published a news story on the trial yesterday.

Stem Cell Reverses Diabetes: Stem Cells from Cord Blood Used to Re-Educate Diabetic's Own T Cells

Source: BioMed Central
Date: January 9, 2012


Type 1 diabetes is caused by the body's own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient's blood glucose levels. A new method described in BioMed Central's open access journal BMC Medicine uses stem cells from cord blood to re-educate a diabetic's own T cells and consequently restart pancreatic function reducing the need for insulin.

StemCells, Inc. Completes Enrollment of First Cohort in Landmark Chronic Spinal Cord Injury Trial

Source: StemCells, Inc.
Date: December 15, 2011


NEWARK, Calif., StemCells, Inc. announced today that the first cohort of the Company's Phase I/II clinical trial in chronic spinal cord injury have been successfully transplanted with the Company's proprietary HuCNS-SC® neural stem cells. This landmark clinical trial has a unique design, in which patients with progressively decreasing severity of injury will be treated in three sequential cohorts. The first cohort of patients all have spinal cord injury classified as AIS A, the most severe level identified by the American Spinal Injury Association Impairment Scale (AIS).

Salk researchers develop safe way to repair sickle cell disease genes New gene editing technique would heal patients with their own cells

Source: Salk Institute for Biological Studies
Date: December 7, 2011


LA JOLLA, CA—Researchers at the Salk Institute for Biological Studies have developed a way to use patients' own cells to potentially cure sickle cell disease and many other disorders caused by mutations in a gene that helps produce blood hemoglobin. The technique uses cells from a patient's skin to generate induced pluripotent stem cells (iPSCs), which are capable of developing into various types of mature tissues—including blood. The scientists say their method, which repairs the beta-globin gene (HBB), avoids gene research techniques that can introduce potentially harmful genes into cells. The new technique, which will soon be tested as a research in animals, also appears to be much more efficient than other methods tested to date, the researchers say. The study appears in the December 2011 issue of Cell Research.

Researchers identify new method for generating stem cell-like cells from human skin

Source: University of California - Los Angeles
Date: December 1, 2011


Researchers from the UCLA School of Dentistry investigating how stem cells can be used to regenerate dental tissue have discovered a way to produce cells with stem cell–like characteristics from the most common type of human skin cell in the epidermis. These skin cells, called keratinocytes, form the outermost layer of skin and can be cultured from discarded skin tissues or biopsy specimens. The findings, published in the Nov. 4 edition of the peer-reviewed Journal of Biological Chemistry, may be beneficial for individuals with limited sources of endogenous stem cells.

Scientists Engineer Blood Stem Cells to Fight Melanoma

Source: University of California - Los Angeles
Date: November 28, 2011


Researchers from UCLA's cancer and stem cell centers have demonstrated for the first time that blood stem cells can be engineered to create cancer-killing T-cells that seek out and attack a human melanoma. The researchers believe this approach could be useful in 40 percent of Caucasians with this malignancy.

Done in mouse models, the study serves as first proof-of-principle that blood stem cells, which make every cell type found in blood, can be genetically altered in a living organism to create an army of melanoma-fighting T-cells, said Jerome Zack, study senior author and a scientist with UCLA's Jonsson Comprehensive Cancer Center and the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. The study appears Nov. 28, 2011 in the early online edition of the peer-reviewed journal Proceedings of the National Academy of SciencesM.

Stem Cell Study Helps Clarify the Best Time for research to Aid Heart Attack Survivors

Source: Mayo Clinic
Date: November 14, 2011


ORLANDO, Fla. A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell research. The results were presented this morning at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They also will be published online in JAMA to coincide with the presentation.